← Back to Screener
Prelude Therapeutics Incorporated (PRLD)
Price$3.81
Value ScoreD
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)118.86%
Price vs S&P 500 (4W)-21.60%
VGM Score65.65
Market Capitalization$303.45M
All Metrics
Book Value / Share (Quarterly)$0.95
P/TBV (Annual)0.93x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.69
Price vs S&P 500 (YTD)23.22%
Net Profit Margin (TTM)-278.51%
EPS (TTM)$-0.59
10-Day Avg Trading Volume0.30M
EPS Excl Extra (TTM)$-0.59
EPS (Annual)$-1.29
ROI (Annual)-144.96%
Cash / Share (Quarterly)$1.29
Revenue Growth QoQ (YoY)41.00%
ROA (Last FY)-70.41%
EBITD / Share (TTM)$-0.64
ROE (5Y Avg)-78.25%
Operating Margin (TTM)-310.66%
Cash Flow / Share (Annual)$-0.90
P/B Ratio5.04x
P/B Ratio (Quarterly)3.58x
Net Income / Employee (Annual)$-1,259,500
EV / Revenue (TTM)16.85x
ROA (TTM)-39.27%
EPS Incl Extra (Annual)$-1.29
Current Ratio (Annual)1.99x
Quick Ratio (Quarterly)1.95x
3-Month Avg Trading Volume0.37M
52-Week Price Return289.49%
Revenue / Employee (TTM)$211,600
Tangible BV / Share (Quarterly)$4.35
P/S Ratio (Annual)25.00x
Asset Turnover (Annual)0.09x
52-Week High$5.54
EPS Excl Extra (Annual)$-1.29
CapEx CAGR (5Y)-35.92%
26-Week Price Return126.79%
Quick Ratio (Annual)1.95x
13-Week Price Return22.12%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.03x
Enterprise Value$281.69M
Asset Turnover (TTM)0.14x
Book Value / Share Growth (5Y)-25.83%
Revenue / Employee (Annual)$153,700
Pretax Margin (Annual)-819.59%
Cash / Share (Annual)$1.64
3-Month Return Std Dev121.64%
Net Income / Employee (TTM)$-589,500
ROE (Last FY)-144.96%
EPS Basic Excl Extra (Annual)$-1.29
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.59
ROI (TTM)-74.57%
P/S Ratio (TTM)18.15x
Revenue / Share (Annual)$0.16
Tangible BV / Share (Annual)$4.08
Price vs S&P 500 (52W)265.13%
Year-to-Date Return31.38%
5-Day Price Return-0.26%
EPS Normalized (Annual)$-1.29
ROA (5Y Avg)-55.14%
Net Profit Margin (Annual)-819.59%
Month-to-Date Return-2.81%
Cash Flow / Share (TTM)$-2.12
EBITD / Share (Annual)$-1.34
Operating Margin (Annual)-861.33%
ROI (5Y Avg)-78.22%
EPS Basic Excl Extra (TTM)$-0.59
P/TBV (Quarterly)0.77x
P/B Ratio (Annual)2.39x
Pretax Margin (TTM)-278.51%
Book Value / Share (Annual)$1.09
Price vs S&P 500 (13W)13.86%
Beta1.00x
Revenue / Share (TTM)$0.20
ROE (TTM)-74.57%
52-Week Low$0.75
vGradeD
gGradeB
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.13est. -0.25
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PRLDPrelude Therapeutics Incorporated | D | B | A | $3.81 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Prelude Therapeutics is a clinical-stage precision oncology company developing small molecule therapies targeting key cancer driver mechanisms in high unmet need indications. The company's pipeline includes four candidates in clinical development: PRT1419 (MCL1 inhibitor), PRT2527 (CDK9 inhibitor), PRT3645 (next-generation CDK4/6 inhibitor), and PRT3789 (first-in-class SMARCA2/BRM protein degrader).